AI THERAPEUTICS
AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics expects to use its disease-specific focus and technological approach to identify and advance drugs that will provide significant therapeutic benefits for LAM patients. AI Therapeutics develops drugs for rare diseases and cancer. LAM ... takes advantage of the inflection point in biological understanding and computer science, leveraging big data from NextGen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.
AI THERAPEUTICS
Industry:
Artificial Intelligence Biotechnology Genetics Medical Therapeutics
Founded:
2013-01-01
Address:
Guilford, Connecticut, United States
Country:
United States
Website Url:
http://www.ai-therapeutics.com
Total Employee:
101+
Status:
Active
Contact:
(203)458-7100
Total Funding:
98 M USD
Technology used in webpage:
Amazon GoDaddy DNS Facebook Sharer Pinterest GoDaddy AWS Global Accelerator GoDaddy Email Amazon Frankfurt Region Reddit
Current Advisors List
Advisor
Board_member
Advisor
2015-01-01
Board_member
Advisor
Advisor
Advisor
Advisor
2015-01-01
Current Employees Featured
Joan Edwards Chief Quality Assurance Officer @ AI Therapeutics
Chief Quality Assurance Officer
Keith Fandrick Chief Development Officer @ AI Therapeutics
Chief Development Officer
2017-05-01
Peter Young Chief Scientific Officer @ AI Therapeutics
Chief Scientific Officer
2021-01-01
Tian Xu Co-Founder @ AI Therapeutics
Co-Founder
Scott Kozak Chief Business Development Officer @ AI Therapeutics
Chief Business Development Officer
2020-12-01
Brigette Roberts CEO @ AI Therapeutics
CEO
2021-12-01
Founder
Investors List
BioVenture
BioVenture investment in Series C - AI Therapeutics
4Catalyzer
4Catalyzer investment in Seed Round - AI Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-16 | AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer |
Official Site Inspections
http://www.ai-therapeutics.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "AI Therapeutics"
OrphAI Therapeutics
GUILFORD,CT, September 28, 2023 — AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has …See details»
OrphAI Therapeutics - Crunchbase Company Profile
AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and …See details»
AI Therapeutics Announces Name Change to OrphAI Therapeutics
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced …See details»
AI THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AI THERAPEUTICS, INC. of Guilford, CT. Get the latest business insights from Dun & Bradstreet.See details»
OrphAI Therapeutics (formerly AI Therapeutics)
AI Therapeutics was founded in 2013 as LAM Therapeutics with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. In 2018 we changed …See details»
AI Therapeutics - Org Chart, Teams, Culture & Jobs | The Org
AI Therapeutics is an AI-driven company with a unique ability to match drugs to indications and prosecute through clinical development. AI Therapeutics’ revolutionary approach to drug …See details»
News - OrphAI Therapeutics
Feb 19, 2025 AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS) April 25, 2022. AI …See details»
OrphAI Therapeutics
Seasoned company builder and advisor with a proven track record of creating value in the biotechnology industry. GUILFORD,CT, July 12,2023 — AI Therapeutics, Inc., a clinical-stage …See details»
AI Therapeutics Company Profile - Office Locations, Competitors
AI Therapeutics (formerly known as LAM Therapeutics) is a company that develops treatments for rare orphan conditions. It offers clinical development, small molecule screening, molecular and …See details»
AI Therapeutics - Products, Competitors, Financials, Employees ...
AI Therapeutics serves the healthcare industry, focusing on developing treatments for rare diseases. AI Therapeutics was formerly known as Lam Therapeutics. It was founded in 2013 …See details»
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of ...
Jan 13, 2022 Promising New Approach for a Fatal Neurological DisorderGUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage …See details»
AI Therapeutics' narrowed ambitions for ALS drug pay off as phase …
Apr 5, 2023 Yale and AI Therapeutics sprang into action in July 2020 after research pointed to apilimod as one of the most likely existing drug candidates to have a therapeutic benefit for …See details»
AI Therapeutics - Overview, News & Similar companies - ZoomInfo
Who is AI Therapeutics. AI Therapeutics was founded by Dr. Jonathan Rothberg, serial entrepreneur and Recipient of the National Medal of Technology and Innovation for inve nting …See details»
AI Therapeutics Announces Name Change to OrphAI
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for...See details»
AI Therapeutics Announces Positive Results from Phase 2a
Apr 5, 2023 AI Therapeutics was founded by Dr. Jonathan Rothberg, serial entrepreneur and Recipient of the National Medal of Technology and Innovation for inventing high speed “Next …See details»
AI Therapeutics Posts First Clinical Data for New ALS Mechanism
Apr 6, 2023 Little-known biopharma company AI Therapeutics announced positive data from its Phase IIa clinical trial in patients with a C9orf72 mutation. Results of the Phase IIa study …See details»
Integrating artificial intelligence in drug discovery and early drug ...
Mar 14, 2025 Artificial intelligence (AI) can transform drug discovery and early drug development by addressing inefficiencies in traditional methods, which often face high costs, long timelines, …See details»
OrphAI Therapeutics
Former Healthcare Investor Takes Helm at Clinical-Stage Biopharmaceutical Company to Advance Life-Saving Treatments for Rare Diseases GUILFORD, CT, February 16, 2022 — AI …See details»
Federal government announces support for cutting-edge, AI- and …
Mar 22, 2025 The Government of Canada is working tirelessly to build up Canada’s life sciences and biomanufacturing sector to develop safe and effective next-generation treatments. Since …See details»
AI Therapeutics: What You Should Know - Digital Health Central
May 18, 2024 AI therapeutics is a dynamic and fast-developing field that is witnessing the emergence of various trends. One of the notable trends is the convergence of AI with other …See details»